Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUV-422 + Enzalutamide in mCRPC
NCT05191017Phase 2Withdrawn
- Sponsor
- Nuvation Bio
- Start
- Sep 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of inixaciclib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Nuvation Bio. Planned start Sep 2022; status: withdrawn.
02
Drugs
inixaciclib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05191017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05191017.